Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Passage BIO, Inc. (PASG)
|
Add to portfolio |
|
|
|
| Price: |
$6.17
| | Metrics |
| OS: |
54.8
|
M
| |
-74
|
% ROE
|
| Market cap: |
$338
|
M
| |
-81
|
% ROIC
|
|
Net cash:
|
$151
|
M
| |
$2.76
|
per share
|
|
EV:
|
$187
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($113)
|
M
| |
|
|
|
EBIT
|
($117)
|
M
| |
|
|
| EPS |
($2.05)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | -3.0 | -8.0 | -1.0 | -0.5 | -3.4 |
| Revenue growth | -62.5% | 700.0% | 100.0% | -85.2% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -3.0 | -8.0 | -1.0 | -0.5 | -3.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 86.1 | 117.7 | 81.8 | 29.7 | 9.2 |
| General and administrative | 49.3 | 60.1 | 30.1 | 7.0 | 0.9 |
| EBIT | -138.4 | -185.7 | -112.9 | -37.2 | -13.5 |
| EBIT margin | 4613.1% | 2321.6% | 11290.2% | 7437.8% | 399.5% |
| Pre-tax income | -136.1 | -185.4 | -112.2 | -45.6 | -12.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -136.1 | -185.4 | -112.2 | -45.6 | -12.8 |
| Net margin | 4537.5% | 2317.3% | 11223.2% | 9126.8% | 378.8% |
| |
| Diluted EPS | ($2.50) | ($3.48) | ($2.91) | ($10.77) | ($3.55) |
| Shares outstanding (diluted) | 54.4 | 53.3 | 38.6 | 4.2 | 3.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|